《Table 1 Characteristics of subjects and donorsa)》
提示：宽带有限、当前游客访问压缩模式
本系列图表出处文件名：随高清版一同展现
《Comparison of efficacy between HLA6/6-and HLA3/6-matched haploidentical hematopoietic stem cell transplant in T-cell-replete transplants between parents and children》
a) ALL，acute lymphoblastic leukemia；AML，acute myeloid leukemia；ATG，thymoglobulin；BM，bone marrow；BU，busulfan；CR，complete remission；CY，cytarabine；MDS，myelodysplastic syndrome；SAA，severe aplastic anemia；NR，non-remission；PB，peripheral blood；PR，part
The OS rates were also comparable between the HLA6/6and the HLA3/6 group（P=0.365）（Figure 4） .OS at 1 year was 83.0%（95%CI=69.1%–99.8%）versus 76.4%（95%CI=65.5%–89.1%），respectively（P=0.471），and OS at3 years was 74.7%（95%CI=56.7%–98.6%）versus 74.0%（95%CI=62.7%–87.3%），respectively（P=0.946）.Multivariate analysis（Table 2）showed donor age（hazard ratio （HR）=1.052；95%CI=1.000–1.100；P=0.028） and disease status（HR=3.547；95%CI=1.257–10.011；P=0.017）were independent risk factors for OS.
| 图表编号 | XD0034727200 严禁用于非法目的 |
|---|---|
| 绘制时间 | 2019.01.05 |
| 作者 | Wenjing Yu、Yu Wang、Depei Wu、Qifa Liu、Lanping Xu、Xiaohui Zhang、Kaiyan Liu、Xiaojun Huang |
| 绘制单位 | Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of Hematopoietic Stem Cell Transplantation、Peking University People's Hospital, Peking University Institute of Hematology, Beijing Key Laboratory of H |
| 更多格式 | 高清、无水印（增值服务） |
